MyLife Technologies, a Leiden-based vaccine and drug delivery startup focusing on ceramic vaccine patches for painless administration through the skin, have raised $4M (approx €3.5M). The investors in the round include Fare Capital, SAL Beheer, informal investors, and other existing shareholders.
FARE Capital invests in the real economy on behalf of institutional investors. The VC firm invests in small and medium-sized enterprises (SME), innovative startups, and scale-ups through long-term financing.
The Dutch company will use the funds to start production of the vaccine patches for clinical studies and invest with partners in demonstration projects against COVID-19, HPV, and vaccine therapy against cancers.
MyLife intends to secure $17.5M (approx €15.2M) in a Series A round in early 2023 for the pilot plant construction and expansion to the US and Asia.